Respiratory
Latest News
June 25th 2025
A phase 2a trial of camlipixant, a selective P2X3 receptor antagonist, found that while the drug did not significantly reduce cough frequency in the overall population with refractory chronic cough, it produced meaningful improvements in patients with a higher baseline cough burden.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Managing Patients With COPD: Evidence-Based Care and Optimizing Value of New and Emerging Targeted Therapies
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Updated Guidance and Managed Care Strategies to Optimize Respiratory Syncytial Virus Vaccination Coverage
Reflecting on the Real-World Use of Biologic Therapy in Asthma Management
Advancing Cystic Fibrosis Management: The Evolving Role of Specialty and Managed Care Pharmacists
Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies
